Acquisition Synergy Leveraging Servier's acquisition of Symphogen to position cross-selling opportunities for antibody discovery platforms, early-stage development services, and CMC biologics capabilities across oncology and immune-oncology portfolios.

Antibody Center Propose expanded collaboration around Symphogen’s established antibody discovery and optimization expertise to accelerate new cancer therapies, including combination strategies, leveraging their Center of Excellence status.

Platform Leverage Offer integrated access to Symphogen’s antibody platform and Gen 3 library capabilities in partnership with Servier’s R&D resources to shorten discovery timelines and improve hit quality for difficult-to-treat tumors.

Strategic Partnerships Target co-development or collaboration deals with CROs, biopharma, and platform providers already engaging with Symphogen, using existing partner signals (Specifica, Cmocro, Thermo Fisher) to fuel outbound outreach.

Global Scale Readiness Align messaging around leveraging Servier’s global footprint and Symphogen’s oncology focus to attract larger pharma alliances, CRO collaborations, and potential manufacturing or supply agreements in biologics.